This is a preview of subscription content, log in via an institution to check access.
References
Original articles
Sanyal, A. J. et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2401755 (2024)
Loomba, R. et al. Tirzepatide for metabolic dysfunction–associated steatohepatitis with liver fibrosis. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2401943 (2024)
Lawitz, E. J. et al. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. J. Hepatol. https://doi.org/10.1016/j.jhep.2024.06.003 (2024)
Sanyal, A. J. et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat. Med. https://doi.org/10.1038/s41591-024-03018-2 (2024)
Related article
Jastreboff, A. M. et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2301972 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kotsiliti, E. Incretin-based therapies for liver disease. Nat Rev Gastroenterol Hepatol (2024). https://doi.org/10.1038/s41575-024-00961-w
Published:
DOI: https://doi.org/10.1038/s41575-024-00961-w
- Springer Nature Limited